(BBIO) BridgeBio Pharma - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 12.927m USD | Total Return: 114% in 12m

Genetic Medicines, TTR Stabilizers, Kinase Inhibitors, Gene Therapy
Total Rating 35
Safety 32
Buy Signal -0.30
Biotechnology
Industry Rotation: -8.2
Market Cap: 12.9B
Avg Turnover: 185M
Risk 3d forecast
Volatility48.9%
VaR 5th Pctl7.32%
VaR vs Median-10.7%
Reward TTM
Sharpe Ratio1.77
Rel. Str. IBD79.8
Rel. Str. Peer Group53.3
Character TTM
Beta1.100
Beta Downside0.901
Hurst Exponent0.329
Drawdowns 3y
Max DD49.08%
CAGR/Max DD1.51
CAGR/Mean DD3.82
EPS (Earnings per Share) EPS (Earnings per Share) of BBIO over the last years for every Quarter: "2021-03": -1.18, "2021-06": -0.66, "2021-09": -1.06, "2021-12": -1.01, "2022-03": -1.19, "2022-06": -0.07, "2022-09": -0.93, "2022-12": -0.92, "2023-03": -0.92, "2023-06": -0.98, "2023-09": -1.08, "2023-12": -0.96, "2024-03": -0.2, "2024-06": -0.39, "2024-09": -0.8596, "2024-12": -1.3744, "2025-03": -0.9888, "2025-06": -0.95, "2025-09": -0.95, "2025-12": -0.9389, "2026-03": -0.84,
Last SUE: -0.55
Qual. Beats: 0
Revenue Revenue of BBIO over the last years for every Quarter: 2021-03: 0.462, 2021-06: 54.024, 2021-09: 2.344, 2021-12: 12.886, 2022-03: 1.694, 2022-06: 73.746, 2022-09: 0.338, 2022-12: 1.87, 2023-03: 1.826, 2023-06: 1.641, 2023-09: 4.091, 2023-12: 1.745, 2024-03: 211.12, 2024-06: 2.168, 2024-09: 2.732, 2024-12: 5.882, 2025-03: 116.633, 2025-06: 110.565, 2025-09: 120.7, 2025-12: 154.18, 2026-03: 194.515,
Rev. CAGR: 371.71%
Rev. Trend: 84.9%
Last SUE: 0.20
Qual. Beats: 0

Warnings

Negative Equity with losses - insolvent profile

Interest Coverage Ratio -5.3 is critical

Beneish M-Score -1.39 > -1.5 - likely earnings manipulation

Altman Z'' -12.53 < 1.0 - financial distress zone

Choppy

Tailwinds

No distinct edge detected

Description: BBIO BridgeBio Pharma

BridgeBio Pharma, Inc. (BBIO) is a commercial-stage biopharmaceutical company focused on genetic diseases and targeted oncology. Its portfolio includes Attruby for transthyretin-mediated amyloidosis (ATTR-CM) and NULIBRY for molybdenum cofactor deficiency, alongside late-stage clinical candidates for achondroplasia, LGMD2I, and Canavan disease. The company utilizes a decentralized hub-and-spoke business model, where individual subsidiaries focus on specific therapeutic programs to minimize cross-project risk while centralizing corporate resources.

The biotechnology sector is characterized by high research and development (R&D) intensity and significant regulatory hurdles before a drug reaches commercialization. BridgeBio mitigates these risks through strategic collaborations with industry leaders such as Bayer, Novartis, and Alexion. For a more granular perspective on these partnerships and the companys valuation metrics, consider exploring the data available on ValueRay. The company continues to advance its pipeline through small molecule therapies and adeno-associated virus (AAV) gene therapy platforms.

Headlines to Watch Out For
  • FDA approval and commercial launch of Attruby for ATTR-CM treatment
  • Phase 3 clinical trial results for low-dose infigratinib in achondroplasia
  • Regulatory milestones and data readouts for Encaleret in ADH1 and CHP
  • Continued access to capital markets to fund late-stage drug development
  • Competitive landscape shifts within the TTR stabilizer and rare disease markets
Piotroski VR‑10 (Strict) 2.5
Net Income: -725.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.33 > 0.02 and ΔFCF/TA 24.66 > 1.0
NWC/Revenue: 62.42% < 20% (prev 426.2%; Δ -363.8% < -1%)
CFO/TA -0.32 > 3% & CFO -444.0m > Net Income -725.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.44 > 1.5 & < 3
Outstanding Shares: last quarter (194.8m) vs 12m ago 2.44% < -2%
Gross Margin: 93.78% > 18% (prev 0.95%; Δ 9.28k% > 0.5%)
Asset Turnover: 51.49% > 50% (prev 14.45%; Δ 37.04% > 0%)
Interest Coverage Ratio: -5.34 > 6 (EBITDA TTM -601.1m / Interest Expense TTM 114.2m)
Altman Z'' -12.53
A: 0.26 (Total Current Assets 1.18b - Total Current Liabilities 816.4m) / Total Assets 1.37b
B: -2.91 (Retained Earnings -3.99b / Total Assets 1.37b)
C: -0.54 (EBIT TTM -610.0m / Avg Total Assets 1.13b)
D: -1.09 (Book Value of Equity -3.99b / Total Liabilities 3.64b)
Altman-Z'' = -12.53 = D
Beneish M -1.39
DSRI: 0.39 (Receivables 205.2m/115.3m, Revenue 580.0m/127.4m)
GMI: 1.02 (GM 93.78% / 95.35%)
AQI: 0.63 (AQ_t 0.12 / AQ_t-1 0.20)
SGI: 4.55 (Revenue 580.0m / 127.4m)
TATA: -0.21 (NI -725.9m - CFO -444.0m) / TA 1.37b)
Beneish M = -1.39 (Cap -4..+1) = D
What is the price of BBIO shares? As of May 23, 2026, the stock is trading at USD 70.28 with a total of 2,242,616 shares traded.
Over the past week, the price has changed by +0.89%, over one month by -7.74%, over three months by +3.49% and over the past year by +114.01%.
Is BBIO a buy, sell or hold? BridgeBio Pharma has received a consensus analysts rating of 4.37. Therefore, it is recommended to buy BBIO.
  • StrongBuy: 10
  • Buy: 6
  • Hold: 3
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the BBIO price?
Analysts Target Price 101.9 45%
BridgeBio Pharma (BBIO) - Fundamental Data Overview as of 21 May 2026
P/S = 22.2893
P/B = 123.6828
Revenue TTM = 580.0m USD
EBIT TTM = -610.0m USD
EBITDA TTM = -601.1m USD
Long Term Debt = 1.93b USD (from longTermDebt, last quarter)
Short Term Debt = 573.4m USD (from shortTermDebt, last quarter)
Debt = 3.40b USD (from shortLongTermDebtTotal, last quarter) + Leases 18.7m
Net Debt = 2.46b USD (calculated: Debt 3.40b - CCE 940.2m)
Enterprise Value = 15.39b USD (12.93b + Debt 3.40b - CCE 940.2m)
Interest Coverage Ratio = -5.34 (Ebit TTM -610.0m / Interest Expense TTM 114.2m)
EV/FCF = -33.89x (Enterprise Value 15.39b / FCF TTM -454.1m)
FCF Yield = -2.95% (FCF TTM -454.1m / Enterprise Value 15.39b)
FCF Margin = -78.30% (FCF TTM -454.1m / Revenue TTM 580.0m)
Net Margin = -125.2% (Net Income TTM -725.9m / Revenue TTM 580.0m)
Gross Margin = 93.78% ((Revenue TTM 580.0m - Cost of Revenue TTM 36.1m) / Revenue TTM)
Gross Margin QoQ = 94.64% (prev 90.0%)
Tobins Q-Ratio = 11.23 (Enterprise Value 15.39b / Total Assets 1.37b)
Interest Expense / Debt = 1.55% (Interest Expense 52.8m / Debt 3.40b)
Taxrate = 21.0% (US default 21%)
NOPAT = -481.9m (EBIT -610.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.44 (Total Current Assets 1.18b / Total Current Liabilities 816.4m)
 Debt / Equity = -1.50 (negative equity) (Debt 3.40b / totalStockholderEquity, last quarter -2.27b)
 Debt / EBITDA = -4.10 (negative EBITDA) (Net Debt 2.46b / EBITDA -601.1m)
 Debt / FCF = -5.42 (negative FCF - burning cash) (Net Debt 2.46b / FCF TTM -454.1m)
 Total Stockholder Equity = -2.02b (last 4 quarters mean from totalStockholderEquity)
RoA = -64.45% (Net Income -725.9m / Total Assets 1.37b)
RoE = -36.87% (Net Income TTM -725.9m / Total Stockholder Equity 1.97b)
RoCE = -15.66% (EBIT -610.0m / Capital Employed (Equity 1.97b + L.T.Debt 1.93b))
 RoIC = -256.5% (out of range, set to none) (NOPAT -481.9m / Invested Capital 187.8m)
 WACC = 8.05% (E(12.93b)/V(16.33b) * Re(9.85%) + D(3.40b)/V(16.33b) * Rd(1.55%) * (1-Tc(0.21)))
Discount Rate = 9.85% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.39 | Cagr: 5.02%
 [DCF] Fair Price = unknown (Cash Flow -454.1m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.55 | # QB: 0
Revenue Correlation: 84.86 | Revenue CAGR: 371.7% | SUE: 0.20 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.58 | Chg30d=-18.37% | Revisions=-43% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.47 | Chg30d=+3.57% | Revisions=+14% | Analysts=4
EPS current Year (2026-12-31): EPS=-2.20 | Chg30d=+0.63% | Revisions=+25% | GrowthEPS=+41.9% | GrowthRev=+91.8%
EPS next Year (2027-12-31): EPS=0.38 | Chg30d=+37.87% | Revisions=+14% | GrowthEPS=+117.1% | GrowthRev=+68.4%
[Analyst] Revisions Ratio: -43%